Russian Federation
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2012 143 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 19 (18–20) 13 (13–14)
Mortality (HIV+TB only) 1.8 (1.5–2.2) 1.2 (1–1.5)
Prevalence  (includes HIV+TB) 170 (73–320) 121 (51–221)
Incidence  (includes HIV+TB) 130 (110–150) 91 (77–106)
Incidence (HIV+TB only) 9.3 (7.9–11) 6.5 (5.5–7.5)
Case detection, all forms (%) 81 (70–96)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 27 467 (28) Relapse 8 211 (16)
Smear-negative 59 019 (61) Treatment after failure 9 109 (17)
Smear-unknown / not done 1 039 (1) Treatment after default 2 593 (5)
Extrapulmonary 10 017 (10) Other 32 466 (62)
Other 0 (0)      
Total new 97 542   Total retreatment 52 379  
           
Other (history unknown) 0        
Total new and relapse 105 753   Total cases notified 149 921  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.7 2.2 1.3
Age < 15 48 730 2 910
Laboratories 2012
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 4.1
Drug susceptibility testing (per 5 million population) 3.8
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 54   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 73  
Retreatment 42  
TB/HIV 2012 Number (%)
TB patients with known HIV status 75 995  
HIV-positive TB patients 4 880  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 23 (21–25) 49 (44–53)
MDR-TB cases among notified pulmonary
TB cases
20 000 (18 000–22 000) 25 000 (23 000–28 000)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 32 647 (79%) 12 324 (24%) 44 971
Laboratory-confirmed MDR-TB cases 6 537 7 075 13 612
Patients started on MDR-TB treatment     18 452
Financing TB control 2013
National TB programme budget (US$ millions) 1 592
% Funded domestically 100%
% Funded internationally <1%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data